123 related articles for article (PubMed ID: 34480084)
1. Comment on: The expression of YAP1 is increased in high-grade prostatic adenocarcinoma but is reduced in neuroendocrine prostate cancer.
Peng B; Sun Y; Wu J; Li Q
Prostate Cancer Prostatic Dis; 2022 Feb; 25(2):373-374. PubMed ID: 34480084
[No Abstract] [Full Text] [Related]
2. The expression of YAP1 is increased in high-grade prostatic adenocarcinoma but is reduced in neuroendocrine prostate cancer.
Cheng S; Prieto-Dominguez N; Yang S; Connelly ZM; StPierre S; Rushing B; Watkins A; Shi L; Lakey M; Baiamonte LB; Fazili T; Lurie A; Corey E; Shi R; Yeh Y; Yu X
Prostate Cancer Prostatic Dis; 2020 Dec; 23(4):661-669. PubMed ID: 32313141
[TBL] [Abstract][Full Text] [Related]
3. Re: The expression of YAP1 is increased in high-grade prostatic adenocarcinoma but is reduced in neuroendocrine prostate cancer.
Yang M; Li J; Li N; Guo H
Prostate Cancer Prostatic Dis; 2021 Dec; 24(4):1212-1213. PubMed ID: 34035458
[No Abstract] [Full Text] [Related]
4. Gene expression signatures of neuroendocrine prostate cancer and primary small cell prostatic carcinoma.
Tsai HK; Lehrer J; Alshalalfa M; Erho N; Davicioni E; Lotan TL
BMC Cancer; 2017 Nov; 17(1):759. PubMed ID: 29132337
[TBL] [Abstract][Full Text] [Related]
5. Variants and unusual patterns of prostate cancer: clinicopathologic and differential diagnostic considerations.
Fine SW
Adv Anat Pathol; 2012 Jul; 19(4):204-16. PubMed ID: 22692283
[TBL] [Abstract][Full Text] [Related]
6. Characterization of transcriptomic signature of primary prostate cancer analogous to prostatic small cell neuroendocrine carcinoma.
Alshalalfa M; Liu Y; Wyatt AW; Gibb EA; Tsai HK; Erho N; Lehrer J; Takhar M; Ramnarine VR; Collins CC; Den RB; Schaeffer EM; Davicioni E; Lotan TL; Bismar TA
Int J Cancer; 2019 Dec; 145(12):3453-3461. PubMed ID: 31125117
[TBL] [Abstract][Full Text] [Related]
7. Neuroendocrine carcinoma of prostate presenting with ascites.
Sagar N; Kushwaha P; Mallya V; Jain S; Khurana N; Hadke NS
J Cancer Res Ther; 2021; 17(2):577-579. PubMed ID: 34121712
[TBL] [Abstract][Full Text] [Related]
8. Neuroendocrine Tumors of the Prostate: Emerging Insights from Molecular Data and Updates to the 2016 World Health Organization Classification.
Priemer DS; Montironi R; Wang L; Williamson SR; Lopez-Beltran A; Cheng L
Endocr Pathol; 2016 Jun; 27(2):123-35. PubMed ID: 26885643
[TBL] [Abstract][Full Text] [Related]
9. A probasin-large T antigen transgenic mouse line develops prostate adenocarcinoma and neuroendocrine carcinoma with metastatic potential.
Masumori N; Thomas TZ; Chaurand P; Case T; Paul M; Kasper S; Caprioli RM; Tsukamoto T; Shappell SB; Matusik RJ
Cancer Res; 2001 Mar; 61(5):2239-49. PubMed ID: 11280793
[TBL] [Abstract][Full Text] [Related]
10. [Neuroendocrine tumors of the prostate].
Bours AF; Jorion JL; Donnay M; Ledent G; Van Ruyssevelt C
Acta Urol Belg; 1993 Sep; 61(3):13-6. PubMed ID: 8256680
[TBL] [Abstract][Full Text] [Related]
11. Prostate adenocarcinoma in a young patient with multiple endocrine neoplasia 2B.
Maqdasy S; Costes-Chalret N; Batisse-Lignier M; Baron S; Tauveron I
Ann Endocrinol (Paris); 2018 Apr; 79(2):86-89. PubMed ID: 29530270
[No Abstract] [Full Text] [Related]
12. Association of intraductal carcinoma of the prostate detected by initial histological specimen and neuroendocrine prostate cancer: A report of three cases.
Ikeda J; Ohe C; Ohsugi H; Matsuda T; Tsuta K; Kinoshita H
Pathol Int; 2021 Sep; 71(9):621-626. PubMed ID: 34297443
[TBL] [Abstract][Full Text] [Related]
13. Neuroendocrine-type prostatic adenocarcinoma with microsatellite instability in a patient with lynch syndrome.
Wagner DG; Gatalica Z; Lynch HT; Kohl S; Johansson SL; Lele SM
Int J Surg Pathol; 2010 Dec; 18(6):550-3. PubMed ID: 20798067
[TBL] [Abstract][Full Text] [Related]
14. Mucin-secreting adenocarcinoma of the prostate with neuroendocrine differentiation and Paneth-like cells.
Van de Voorde W; Van Poppel H; Haustermans K; Baert L; Lauweryns J
Am J Surg Pathol; 1994 Feb; 18(2):200-7. PubMed ID: 8291659
[TBL] [Abstract][Full Text] [Related]
15. Comparative study of neuroendocrine acquisition and biomarker expression between neuroendocrine and usual prostatic carcinoma.
Xiao GQ; Ho G; Suen C; Hurth KM
Prostate; 2021 Jun; 81(8):469-477. PubMed ID: 33848377
[TBL] [Abstract][Full Text] [Related]
16. Molecular Subtypes of High-Grade Neuroendocrine Carcinoma (HGNEC): What is YAP1-Positive HGNEC?
Kawai H; Matsuoka R; Ito T; Matsubara D
Front Biosci (Landmark Ed); 2022 Mar; 27(3):108. PubMed ID: 35345340
[TBL] [Abstract][Full Text] [Related]
17. A pure primary low-grade neuroendocrine carcinoma (carcinoid tumor) of the prostate.
Giordano S; Tolonen T; Tolonen T; Hirsimäki S; Kataja V
Int Urol Nephrol; 2010 Sep; 42(3):683-7. PubMed ID: 19866370
[TBL] [Abstract][Full Text] [Related]
18. Telomere lengths differ significantly between small-cell neuroendocrine prostate carcinoma and adenocarcinoma of the prostate.
Heaphy CM; Haffner MC; Graham MK; Lim D; Davis C; Corey E; Epstein JI; Eisenberger MA; Wang H; De Marzo AM; Meeker AK; Lotan TL
Hum Pathol; 2020 Jul; 101():70-79. PubMed ID: 32389660
[TBL] [Abstract][Full Text] [Related]
19. Primary large cell neuroendocrine carcinoma of the prostate in a hormone naive patient: A case report from Taiwan.
Tzou KY; Cheng WH; Lee WH; Ho CH
J Cancer Res Ther; 2018 Sep; 14(Supplement):S785-S788. PubMed ID: 30249904
[TBL] [Abstract][Full Text] [Related]
20. Neuroendocrine differentiation of prostate cancer.
Li Z; Chen CJ; Wang JK; Hsia E; Li W; Squires J; Sun Y; Huang J
Asian J Androl; 2013 May; 15(3):328-32. PubMed ID: 23503426
[No Abstract] [Full Text] [Related]
[Next] [New Search]
